Biomarin Pharmaceutical Inc (BMRN)
66.60
+0.71
(+1.08%)
USD |
NASDAQ |
Nov 01, 16:00
66.60
0.00 (0.00%)
After-Hours: 20:00
Biomarin Pharmaceutical PE Ratio: 39.88 for Nov. 1, 2024
PE Ratio Chart
Historical PE Ratio Data
| Date | Value |
|---|---|
| November 01, 2024 | 39.88 |
| October 31, 2024 | 39.46 |
| October 30, 2024 | 39.93 |
| October 29, 2024 | 41.86 |
| October 28, 2024 | 41.99 |
| October 25, 2024 | 41.75 |
| October 24, 2024 | 42.15 |
| October 23, 2024 | 41.90 |
| October 22, 2024 | 42.23 |
| October 21, 2024 | 42.08 |
| October 18, 2024 | 41.98 |
| October 17, 2024 | 41.60 |
| October 16, 2024 | 42.01 |
| October 15, 2024 | 42.19 |
| October 14, 2024 | 42.08 |
| October 11, 2024 | 42.13 |
| October 10, 2024 | 41.83 |
| October 09, 2024 | 41.80 |
| October 08, 2024 | 41.13 |
| October 07, 2024 | 41.29 |
| October 04, 2024 | 41.62 |
| October 03, 2024 | 40.81 |
| October 02, 2024 | 41.71 |
| October 01, 2024 | 41.98 |
| September 30, 2024 | 42.09 |
| Date | Value |
|---|---|
| September 27, 2024 | 53.07 |
| September 26, 2024 | 52.81 |
| September 25, 2024 | 51.89 |
| September 24, 2024 | 52.24 |
| September 23, 2024 | 51.98 |
| September 20, 2024 | 53.15 |
| September 19, 2024 | 53.69 |
| September 18, 2024 | 53.49 |
| September 17, 2024 | 53.05 |
| September 16, 2024 | 52.53 |
| September 13, 2024 | 63.83 |
| September 12, 2024 | 63.44 |
| September 11, 2024 | 63.74 |
| September 10, 2024 | 63.80 |
| September 09, 2024 | 63.41 |
| September 06, 2024 | 63.22 |
| September 05, 2024 | 64.00 |
| September 04, 2024 | 67.56 |
| September 03, 2024 | 68.87 |
| August 30, 2024 | 68.58 |
| August 29, 2024 | 68.70 |
| August 28, 2024 | 67.91 |
| August 27, 2024 | 68.02 |
| August 26, 2024 | 67.65 |
| August 23, 2024 | 67.68 |
Price to Earnings Ratio (PE Ratio) Definition
The Price to Earnings Ratio (PE Ratio) is calculated by taking the stock price / EPS Diluted (TTM). This metric is considered a valuation metric that confirms whether the earnings of a company justifies the stock price. There isn't necesarily an optimum PE ratio, since different industries will have different ranges of PE Ratios. Because of this, PE Ratio is great to evaluate from a relative standpoint with other similar companies.
PE Ratio Range, Past 5 Years
16.62
Minimum
Nov 03 2020
1143.38
Maximum
Nov 19 2021
193.72
Average
122.34
Median
PE Ratio Benchmarks
| Merck & Co Inc | 21.36 |
| Bristol-Myers Squibb Co | -- |
| Alnylam Pharmaceuticals Inc | -- |
| Bioventus Inc | -- |
| Moderna Inc | -- |
PE Ratio Related Metrics
| PS Ratio | 4.750 |
| PEG Ratio | 0.3401 |
| Price to Book Value | 2.345 |
| Price to Free Cash Flow | 43.46 |
| Price | 66.60 |
| Earnings Yield | 2.51% |
| Market Cap | 12.69B |
| PEGY Ratio | 0.3401 |
| Operating PE Ratio | 41.86 |
| Normalized PE Ratio | 40.91 |